These WHO guidelines which were updated in 2018, are valid for any country and suitable to local adaptations, and take account of the strength of available scientific evidence, the cost and resource implications, and patient values and preferences.
The 2018 edition of the guidelines includes the re...vision of the recommendation regarding the use of 80% fraction of inspired oxygen (high FiO2) in surgical patients under general anaesthesia with tracheal intubation and the update of the section on implementation. Between 2017 and 2018, WHO re-assessed the evidence on the use of high FiO2 by updating the systematic review related to the effectiveness of this intervention to reduce SSI and commissioning an independent systematic review on adverse events potentially associated with it. Based on the updated evidence, the GDG decided to revise the strength of the recommendation from strong to conditional.
more
Community Care Centres (CCCs) are small facilities (10 beds maximum), located within the community and run by community health workers. CCCs provide isolation facilities for Ebola patients in order to prevent further transmission of the virus within their households and communities. People with Ebol...a virus can also receive basic curative and palliative care in these centres in an environment supported by their family and communities. This document describes key principles and main considerations for implementation of a community approach.
more
. Interim Guidelines. This interim guideline lays out some basic principles of optimal nutritional care for adults and paediatric patients during treatment and convalescence in Ebola treatment units, community care centres or to other centres where Ebola patients are receiving care and support. It h...ighlights the key clinical problems in patients affected by Ebola virus disease (EVD) that may interfere with their nutritional status and overall clinical support in the context of the current Ebola crisis, and summarizes their nutritional needs. It does not provide specific advice on fluid management in cases of vomiting, diarrhoea and dehydration or parenteral nutrition
more
Ce manuel décrit les règles et les procédures mises en place pour assurer la qualité
des prestations faites par le service de Pharmacie de l’hôpital d’Aubenas.
Il s’applique à toutes les prestations faites par le service de Pharmacie à destination des
différents services de l’hôp...ital ainsi qu’aux patients en ambulatoire sollicitant la pharmacie.
Basé sur le modèle de la norme AFNOR ISO 9001 version 2000, sa finalité est d’accroître la
satisfaction des unités de soins et se conformer aux bonnes pratiques de pharmacie
hospitalière.
more
mBio, Vol. 6 Issue 2, March/April 2015
Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, but this is based on a limited number of studies. In this review, the authors address what we know and what ...we do not know about Ebola virus transmission. They also hypothesize that Ebola viruses have the potential to be respiratory pathogens with primary respiratory spread.
more
This booklet avises on how to deal with unexpected emotions; changes in family routines and the relationship with the patient; Offers helpful tips on how to advocate for the patient within the health system and the community; Helps caregivers know what to expect when the end of life is near; Gi...ves tips on how to ask others for help; self-care.
more
The International Textbook of Leprosy is dedicated to the physicians and health workers caring for their first patient with leprosy, and to all of those in the research community who have encountered some of the fascinating scientific aspects of leprosy and wish to learn more. Read online at: http:/.../www.internationaltextbookofleprosy.org/
more
This is a basic form for reporting individual cases of plague. It asks for information regarding patient history and the course of the illness. In addition, it offers space for laboratory results, the case status, and epidemiological information.
Antimicrobial stewardship (AMS) describes a coherent set of actions that ensure optimal use of antimicrobials to improve patient outcomes, while limiting the risk of adverse events (including antimicrobial resistance (AMR)). Introduction of AMS programmes in hospitals is part of most national action... plans to mitigate AMR, yet the optimal components and actions of such a programme remain undetermined.
more
UpToDate® Guest Pass
COVID-19 Clinical Topics in UpToDate
Clinical Drug Information in Lexicomp®
COVID-19 Content as a Service (CaaS)
Patient Information and Resources
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
Note technique. Les centres de traitement de choléra fournissent des soins hospitaliers aux patients atteints de choléra
pendant les épidémies. Une prise en charge de qualité et l’isolement des patients atteints du choléra sont
essentiels pour prévenir les décès et aider à lutter con...tre la propagation de la maladie. Traditionnellement,
ces structures sont appelées centres de traitement du choléra (CTC) et unités de traitement du choléra (UTC).
Les CTC sont généralement de grandes structures mises en place au niveau central (zones urbaines, par
exemple), tandis que les UTC sont des structures plus petites, installées en périphérie (zones périurbaines ou
rurales, par exemple). Les CTC/UTC peuvent être mis en place en tant que structures indépendantes dans
des tentes ou à l’intérieur de bâtiments existants ou dans des unités sanitaires. Quelle que soit la structure,
les principes décrits dans ce document doivent être respectés.
more
Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim...ited. Pathogenesis of the characteristic painless ulcers is linked to the elaboration by M. ulcerans of a lipid toxin called mycolactone that has potent cytopathic, immunosuppressive, and analgesic effects on a host of cells in cutaneous tissues. Mycolactone is known to profoundly inhibit secretion of a plethora of proteins that are essential for wound healing. Even though a combination antibacterial therapy of streptomycin and rifampicin for 8 weeks is effective for treatment, it relies on good and appropriate wound management to prevent secondary bacterial infections and improve healing. Evidence-based interventions for wound care in Buruli ulcer disease are often lacking and have relied on expert advice and recommendations. Surgical interventions are limited to debridement of necrotic tissue and grafting of extensive ulcers, usually after antibiotic therapy. Patients’ rehabilitation is an important component of care to reduce disabilities associated with the disease and proper integration into the community after treatment.
more
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more
At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified
treatment which can be orally administered, impl...emented at the primary health care level, and effective against both stages of the disease.
more
Le présent manuel a pour but de fournir des orientations concernant la conception,
l’organisation et l’évaluation d’un cours visant à établir et à renforcer les capacités des
personnels de santé pour qu’ils puissent prendre en charge les patients ophtalmiques dans
les établissemen...ts de soins de santé primaires dans la Région africaine. Le cours s’inscrit dans
le cadre du perfectionnement professionnel continu au sens le plus large du terme. Son
contenu met l’accent sur des pratiques simples fondées sur des données factuelles que l’on
peut facilement appliquer dans des établissements de soins de santé primaires partout en
Afrique.
more
Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev...ent, “Trust and transformation are key words for us, especially when we talk about improving and strengthening our health systems. Transformation should first and foremost serve the interests of patients and health-care workers”.
While it is not always easy to demonstrate the immediate effect of guidelines on people’s health, there is no viable alternative to utilizing guidelines based on the best available evidence.
Yet, developing robust guidelines remains a challenge for most countries. “Guidelines need to be both simple to use and timely, they need to address people’s real needs, especially at the local level, and should ultimately reflect the resources available,” said Dr Natasha Azzopardi-Muscat, Director, Country Health Policies and Systems, WHO/Europe. “This means that any successful guideline needs to be adjusted and adapted to local contexts and realities.”
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
The new Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact 1 aim to help countries improve how routine patient data are collected, analysed and used. They propose a minimum dataset that captures key events in an individual’s interaction with ...the health system, put forward priority indicators for monitoring a person’s health, and make key recommendations for data systems and data use.
more